B-cell maturation antigen (BCMA) is a promising therapeutic target for multiple myeloma (MM),
but expression is variable, and early reports of BCMA targeting chimeric antigen …

Purpose: Immune dysregulation is described in multiple myeloma. While preclinical models
suggest a role for altered T-cell immunity in disease progression, the contribution of immune …

Patients with multiple myeloma, an incurable malignancy of plasma cells, frequently develop
osteolytic bone lesions that severely impact quality of life and clinical outcomes. Eliglustat, …

… Lydia Lee, 1 Wen Chean Lim, 2 Daria Galas-Filipowicz, 1 Kent Fung, 1 Julia Taylor, 2
Dominic Patel, 3 Zulaikha Akbar, 2 Elena Alvarez Mediavilla, 1 Patrycja Wawrzyniecka, 4 …

The benefit of autologous stem cell transplantation (ASCT) in newly diagnosed myeloma
patients, apart from supporting high dose chemotherapy, may include effects on T cell function …

Background Achieving minimal residual disease (MRD) negativity following treatment for
multiple myeloma (MM) is associated with improved progression free and overall survival. In …

BACKGROUND: The etiology of nonsyndromic cleft lip with or without cleft palate (NSCL/P)
is very complex and still not well elucidated. Given the critical role of DNA damage repair in …

Precision medicine holds great promise to improve outcomes in cancer, including
haematological malignancies. However, there are few biomarkers that influence choice of …

T cell receptors (TCRs) play a crucial role in orchestrating cellular immunity in both health
and disease, particularly in the context of cancer. Although immunotherapy and stem cell …

Autologous stem cell transplant (ASCT) is the current standard of care for eligible patients
with multiple myeloma (MM). The UK national trial CARDAMON investigated whether, …